Point-of-Care HbA1c in Clinical Practice: Caveats and Considerations for Optimal Use

Overview

Journal Diabetes Care

Specialty Endocrinology

Date 2024 Mar 29

PMID 38552140

Authors

David B Sacks

M Sue Kirkman

Randie R Little

Affiliations

Soon will be listed here.

Abstract

Hemoglobin A1c (A1C) is widely used for the diagnosis and management of diabetes. Accurate measurement of A1C is necessary for optimal clinical value. Assay standardization has markedly improved the accuracy and consistency of A1C testing. Devices to measure A1C at point of care (POC) are commercially available, allowing rapid results when the patient is seen. In this review, we describe how standardization of A1C testing was achieved, leading to high-quality results in clinical laboratories. We address the use of POC A1C testing in clinical situations and summarize the advantages and disadvantages of POC A1C testing. We emphasize the importance of considering the limitations of these devices and following correct testing procedures to ensure that accurate A1C results are obtained for optimal care of patients.

Citing Articles

A patient choice-driven lifestyle intervention lowers HbA1c in type 2 diabetes: A feasibility study.

Weeldreyer N, McEntee M, Martin M, Lee C, Marvasti F, Gaesser G Physiol Rep. 2025; 13(2):e70163.

PMID: 39815443 PMC: 11735460. DOI: 10.14814/phy2.70163.

Glycated Haemoglobin (HbA) in Cardiac Surgery: A Narrative Review.

Luthra S, Viola L, Navaratnarajah M, Thirukumaran D, Velissaris T J Clin Med. 2025; 14(1.

PMID: 39797106 PMC: 11721050. DOI: 10.3390/jcm14010023.

References

Weatherall D, Clegg J . Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ. 2001; 79(8):704-12. PMC: 2566499. View

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

Lenters-Westra E, Slingerland R . Hemoglobin A1c point-of-care assays; a new world with a lot of consequences!. J Diabetes Sci Technol. 2010; 3(3):418-23. PMC: 2769862. DOI: 10.1177/193229680900300303. View

Torregrosa M, Molina J, Argente C, Ena J . Accuracy of three hemoglobin A1c point-of-care systems for glucose monitoring in patients with diabetes mellitus. Endocrinol Nutr. 2015; 62(10):478-84. DOI: 10.1016/j.endonu.2015.07.007. View

Hansen G . Point-of-Care Testing in Microbiology: A Mechanism for Improving Patient Outcomes. Clin Chem. 2019; 66(1):124-137. DOI: 10.1373/clinchem.2019.304782. View

. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010; 33 Suppl 1:S62-9. PMC: 2797383. DOI: 10.2337/dc10-S062. View

Abildgaard A, Knudsen C, Bjerg L, Lund S, Stoy J . Lot variation and inter-device differences contribute to poor analytical performance of the DCA Vantage™ HbA POCT instrument in a true clinical setting. Clin Chem Lab Med. 2021; 60(1):127-134. DOI: 10.1515/cclm-2021-0720. View

Petersen J, Finley J, Okorodudu A, Mohammad A, Grady J, Bajaj M . Effect of point-of-care on maintenance of glycemic control as measured by A1C. Diabetes Care. 2007; 30(3):713-5. DOI: 10.2337/dc06-1909. View

Holman R, Paul S, Bethel M, Matthews D, Neil H . 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15):1577-89. DOI: 10.1056/NEJMoa0806470. View

10.

Lenters-Westra E, Slingerland R . Six of eight hemoglobin A1c point-of-care instruments do not meet the general accepted analytical performance criteria. Clin Chem. 2009; 56(1):44-52. DOI: 10.1373/clinchem.2009.130641. View

11.

Kobold U, JEPPSSON J, Dulffer T, Finke A, Hoelzel W, Miedema K . Candidate reference methods for hemoglobin A1c based on peptide mapping. Clin Chem. 1997; 43(10):1944-51. View

12.

. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2024. Diabetes Care. 2023; 47(Suppl 1):S282-S294. PMC: 10725801. DOI: 10.2337/dc24-S015. View

13.

Khunti K, Stone M, Burden A, Turner D, Raymond N, Burden M . Randomised controlled trial of near-patient testing for glycated haemoglobin in people with type 2 diabetes mellitus. Br J Gen Pract. 2006; 56(528):511-7. PMC: 1872061. View

14.

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

15.

. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009; 32(7):1327-34. PMC: 2699715. DOI: 10.2337/dc09-9033. View

16.

Cagliero E, Levina E, Nathan D . Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients. Diabetes Care. 1999; 22(11):1785-9. DOI: 10.2337/diacare.22.11.1785. View

17.

Roberts W, Safar-Pour S, De B, Rohlfing C, Weykamp C, Little R . Effects of hemoglobin C and S traits on glycohemoglobin measurements by eleven methods. Clin Chem. 2005; 51(4):776-8. DOI: 10.1373/clinchem.2004.047142. View

18.

Nathan D, Cleary P, Backlund J, Genuth S, Lachin J, Orchard T . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25):2643-53. PMC: 2637991. DOI: 10.1056/NEJMoa052187. View

19.

Leca V, Ibrahim Z, Lombard-Pontou E, Maraninchi M, Guieu R, Portugal H . Point-of-care measurements of HbA(1c): simplicity does not mean laxity with controls. Diabetes Care. 2012; 35(12):e85. PMC: 3507609. DOI: 10.2337/dc12-0751. View

20.

Little R, Rohlfing C, Sacks D . Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clin Chem. 2010; 57(2):205-14. DOI: 10.1373/clinchem.2010.148841. View